Published: 2018-10-25

Effectiveness of pneumococcal vaccine in patients with chronic obstructive pulmonary disease (COPD)

Thitta Mohanty, Mahismita Patro, Jyotirmaya Sahoo, Bijaya Kumar Meher, Manoranjan Pattnaik, Jeetendra Kumar Patra


Background: Pneumococcal infections are frequent cause chronic obstructive pulmonary disease (COPD) exacerbations and though various guidelines recommend the use of pneumococcal vaccines routinely to COPD patients to prevent exacerbations, the data regarding the effectiveness of this vaccine is limited and contradictory. Aims and objectives was to compare the frequency of exacerbations in patients of COPD before and after administration of pneumococcal vaccine and to find out the frequency of exacerbations in patients of COPD who are vaccinated against those who are not vaccinated as well as to study the effectiveness of pneumococcal vaccine will be analysed in respect to age, sex, Body mass index (BMI), severity of disease and other co-morbidity.

Methods: This was a randomized non-placebo controlled trial, conducted from September 2013 to August 2015 including total of 150 patients divided into two groups: cases and controls. The cases were administered PPV23 along with specific medication and were followed up at intervals of 3months. Exacerbations were identified based on ANTHONISEN’S criteria. Number of exacerbations in each follow-up was recorded. The data from both the groups were analysed statistically.

Results: After 1 year of follow up, there was significant reduction in mean number of exacerbations (p value <0.0001) in patients with COPD in vaccinated group. PPV23 was more effective in patients with COPD of less than 65 years of age and with severe and/or very severe airflow obstruction and also in patients with lower BMI (≤21kg/m2), females and with co-morbidities.

Conclusions: This is an important strategy to prevent the repeated exacerbations in COPD patients particularly in severe and very severe disease groups and we support the recommendation that pneumococcal vaccine should be administered to these patients.


COPD, Pneumococcal vaccine

Full Text:



Daniels JM, Boersma WG. Criteria for antibiotic therapy in acute exacerbations of COPD. Am J Res Crit Care Med. 2010 Nov 1;182(9):1207-8.

Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the Diagnosis, Management And prevention of chronic obstructive pulmonary disease, 2017. Available at:

Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals Inter Med. 1987;106(2):196-204.

Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23 valent pneumococcal polysaccharide vaccine (PPSV23), 2010. Available at:

Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Archives Inter Med. 1999 Nov 8;159(20):2437-42.

Franzen D, Clinical efficacy of pneumococcal vaccination-a prospective study in patients with longstanding emphysema and/bronchitis. Eur J Med Res. 2000;5:537-40.

Lee TA, Weaver FM, Weiss KB. Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma. J Gen Inter Med. 2007;22(1):62-7.

Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006 Mar;61(3):189-95.

Schembri S, Morant S, Winter JH, et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64:567-72.

Walters JAE, Tang JNQ, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2017;(1).